In Law360, Global Team Examines How Distributors Expose Health and Life Sciences Companies to FCPA Risks

In The News
August 15, 2018

A cross-border team examined how third-party distributors can expose health care and life sciences companies with operations in the U.S. and abroad to increased liability and risks to the U.S. Foreign Corrupt Practices Act and other nations’ anti-corruption laws in an August 14 Law360 article.

The article was co-authored by health care counsel Alison Fethke (Chicago) and litigation & enforcement associate Tina Yu (London & Hong Kong).

The authors address enforcement of anti-corruption laws and improper third-party actions, and guidance for health care and life sciences companies’ compliance programs.